Startseite>>Signaling Pathways>> Microbiology & Virology>> HIV>>Decanoyl-RVKR-CMK TFA

Decanoyl-RVKR-CMK TFA (Synonyms: DecRVKRcmk TFA)

Katalog-Nr.GC64270

Decanoyl-RVKR-CMK (DecRVKRcmk) TFA hemmt die Überexprimierte gp160-Verarbeitung und die HIV-1-Replikation.

Products are for research use only. Not for human use. We do not sell to patients.

Decanoyl-RVKR-CMK TFA Chemische Struktur

Cas No.: 2098497-25-5

Größe Preis Lagerbestand Menge
5 mg
585,00 $
Auf Lager
10 mg
945,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Decanoyl-RVKR-CMK (DecRVKRcmk) TFA inhibits over-expressed gp160 processing and HIV-1 replication[1].

Decanoyl-RVKR-CMK (DecRVKRcmk) TFA inhibits HIV-2ROD replication by blocking envelope glycoprotein precursor processing in the Jurkat lymphocyte cell[1].Decanoyl-RVKR-CMK (DecRVKRcmk) TFA blocks regulated secretion of VGF[2].

[1]. B Bahbouhi, et al. Inhibition of HIV-2(ROD) replication in a lymphoblastoid cell line by the alpha1-antitrypsin Portland variant (alpha1-PDX) and the decRVKRcmk peptide: comparison with HIV-1(LAI). Microbes Infect. 2001 Nov;3(13):1073-84.
[2]. Angelo L Garcia, et al. A prohormone convertase cleavage site within a predicted alpha-helix mediates sorting of the neuronal and endocrine polypeptide VGF into the regulated secretory pathway. J Biol Chem. 2005 Dec 16;280(50):41595-608.

Bewertungen

Review for Decanoyl-RVKR-CMK TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Decanoyl-RVKR-CMK TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.